The following IPOs are expected to price this week:
Regado Biosciences (RGDO), which is developing break-through anticoagulant system for cardiovascular surgeries, plans to raise $75 million by offering 5.0 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, Regado Biosciences would command a market value of $219 million. Regado Biosciences, which was founded in 2001, booked $0 million in sales over the last 12 months. The Basking Ridge, NJ-based company plans to list on the NASDAQ under the symbol RGDO. Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal.
Renaissance Capital will have Pre-IPO Research available on each of these upcoming IPOs prior to its pricing.
